FDA RATING OF PHARMACOECONOMIC STUDIES ENDORSED BY 59% OF MANAGED CARE PHARMACIES -- MEDTAP's LUCE; HHS IG STUDYING PBM SERVICES TO MCOs
A majority of pharmacy decisionmakers at large managed care organizations favor peer review and an FDA rating system for pharmacoeconomic studies conducted by pharmaceutical companies, MedTap International CEO Bryan Luce, PhD, told a D.C. Bar Association Health Law Section luncheon May 8.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth